Loading
Latest filing published 13 Feb 2026 for Enanta Pharmaceuticals INC.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Tara Lynn Kieffer, listed as senior executive, appears in our data through filings on Enanta Pharmaceuticals Inc shares, published by SEC (Form 4). In total, 23 filings cover trades dated from 19 November 2021 to 12 February 2026.
No open-market purchase appears, only 4 sales worth €145k. The rest of the record consists of 19 share grants.
Most recently, on 13 February 2026, the filings show a share grant worth €39k in Enanta Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations